Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (Cancer Chemotherapy and Pharmacology, (2018), 82, 3, (407-418), 10.1007/s00280-018-3623-7)

Amita Patnaik, Michael Gordon, Frank Tsai, Kyriakos P. Papadopoulos, Drew Rasco, Muralidhar Beeram, Siqing Fu, Filip Janku, Scott M. Hynes, Sushma R. Gundala, Melinda D. Willard, Wei Zhang, Aimee Bence Lin, David Hong

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer (Cancer Chemotherapy and Pharmacology, (2018), 82, 3, (407-418), 10.1007/s00280-018-3623-7)'. Together they form a unique fingerprint.

Medicine & Life Sciences